Tag Archives: big
#431671 The Doctor in the Machine: How AI Is ...
Artificial intelligence has received its fair share of hype recently. However, it’s hype that’s well-founded: IDC predicts worldwide spend on AI and cognitive computing will culminate to a whopping $46 billion (with a “b”) by 2020, and all the tech giants are jumping on board faster than you can say “ROI.” But what is AI, exactly?
According to Hilary Mason, AI today is being misused as a sort of catch-all term to basically describe “any system that uses data to do anything.” But it’s so much more than that. A truly artificially intelligent system is one that learns on its own, one that’s capable of crunching copious amounts of data in order to create associations and intelligently mimic actual human behavior.
It’s what powers the technology anticipating our next online purchase (Amazon), or the virtual assistant that deciphers our voice commands with incredible accuracy (Siri), or even the hipster-friendly recommendation engine that helps you discover new music before your friends do (Pandora). But AI is moving past these consumer-pleasing “nice-to-haves” and getting down to serious business: saving our butts.
Much in the same way robotics entered manufacturing, AI is making its mark in healthcare by automating mundane, repetitive tasks. This is especially true in the case of detecting cancer. By leveraging the power of deep learning, algorithms can now be trained to distinguish between sets of pixels in an image that represents cancer versus sets that don’t—not unlike how Facebook’s image recognition software tags pictures of our friends without us having to type in their names first. This software can then go ahead and scour millions of medical images (MRIs, CT scans, etc.) in a single day to detect anomalies on a scope that humans just aren’t capable of. That’s huge.
As if that wasn’t enough, these algorithms are constantly learning and evolving, getting better at making these associations with each new data set that gets fed to them. Radiology, dermatology, and pathology will experience a giant upheaval as tech giants and startups alike jump in to bring these deep learning algorithms to a hospital near you.
In fact, some already are: the FDA recently gave their seal of approval for an AI-powered medical imaging platform that helps doctors analyze and diagnose heart anomalies. This is the first time the FDA has approved a machine learning application for use in a clinical setting.
But how efficient is AI compared to humans, really? Well, aside from the obvious fact that software programs don’t get bored or distracted or have to check Facebook every twenty minutes, AI is exponentially better than us at analyzing data.
Take, for example, IBM’s Watson. Watson analyzed genomic data from both tumor cells and healthy cells and was ultimately able to glean actionable insights in a mere 10 minutes. Compare that to the 160 hours it would have taken a human to analyze that same data. Diagnoses aside, AI is also being leveraged in pharmaceuticals to aid in the very time-consuming grunt work of discovering new drugs, and all the big players are getting involved.
But AI is far from being just a behind-the-scenes player. Gartner recently predicted that by 2025, 50 percent of the population will rely on AI-powered “virtual personal health assistants” for their routine primary care needs. What this means is that consumer-facing voice and chat-operated “assistants” (think Siri or Cortana) would, in effect, serve as a central hub of interaction for all our connected health devices and the algorithms crunching all our real-time biometric data. These assistants would keep us apprised of our current state of well-being, acting as a sort of digital facilitator for our personal health objectives and an always-on health alert system that would notify us when we actually need to see a physician.
Slowly, and thanks to the tsunami of data and advancements in self-learning algorithms, healthcare is transitioning from a reactive model to more of a preventative model—and it’s completely upending the way care is delivered. Whether Elon Musk’s dystopian outlook on AI holds any weight or not is yet to be determined. But one thing’s certain: for the time being, artificial intelligence is saving our lives.
Image Credit: Jolygon / Shutterstock.com Continue reading
Posted in Human Robots
#431559 Drug Discovery AI to Scour a Universe of ...
On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]
In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading
Posted in Human Robots
#431385 Here’s How to Get to Conscious ...
“We cannot be conscious of what we are not conscious of.” – Julian Jaynes, The Origin of Consciousness in the Breakdown of the Bicameral Mind
Unlike the director leads you to believe, the protagonist of Ex Machina, Andrew Garland’s 2015 masterpiece, isn’t Caleb, a young programmer tasked with evaluating machine consciousness. Rather, it’s his target Ava, a breathtaking humanoid AI with a seemingly child-like naïveté and an enigmatic mind.
Like most cerebral movies, Ex Machina leaves the conclusion up to the viewer: was Ava actually conscious? In doing so, it also cleverly avoids a thorny question that has challenged most AI-centric movies to date: what is consciousness, and can machines have it?
Hollywood producers aren’t the only people stumped. As machine intelligence barrels forward at breakneck speed—not only exceeding human performance on games such as DOTA and Go, but doing so without the need for human expertise—the question has once more entered the scientific mainstream.
Are machines on the verge of consciousness?
This week, in a review published in the prestigious journal Science, cognitive scientists Drs. Stanislas Dehaene, Hakwan Lau and Sid Kouider of the Collège de France, University of California, Los Angeles and PSL Research University, respectively, argue: not yet, but there is a clear path forward.
The reason? Consciousness is “resolutely computational,” the authors say, in that it results from specific types of information processing, made possible by the hardware of the brain.
There is no magic juice, no extra spark—in fact, an experiential component (“what is it like to be conscious?”) isn’t even necessary to implement consciousness.
If consciousness results purely from the computations within our three-pound organ, then endowing machines with a similar quality is just a matter of translating biology to code.
Much like the way current powerful machine learning techniques heavily borrow from neurobiology, the authors write, we may be able to achieve artificial consciousness by studying the structures in our own brains that generate consciousness and implementing those insights as computer algorithms.
From Brain to Bot
Without doubt, the field of AI has greatly benefited from insights into our own minds, both in form and function.
For example, deep neural networks, the architecture of algorithms that underlie AlphaGo’s breathtaking sweep against its human competitors, are loosely based on the multi-layered biological neural networks that our brain cells self-organize into.
Reinforcement learning, a type of “training” that teaches AIs to learn from millions of examples, has roots in a centuries-old technique familiar to anyone with a dog: if it moves toward the right response (or result), give a reward; otherwise ask it to try again.
In this sense, translating the architecture of human consciousness to machines seems like a no-brainer towards artificial consciousness. There’s just one big problem.
“Nobody in AI is working on building conscious machines because we just have nothing to go on. We just don’t have a clue about what to do,” said Dr. Stuart Russell, the author of Artificial Intelligence: A Modern Approach in a 2015 interview with Science.
Multilayered consciousness
The hard part, long before we can consider coding machine consciousness, is figuring out what consciousness actually is.
To Dehaene and colleagues, consciousness is a multilayered construct with two “dimensions:” C1, the information readily in mind, and C2, the ability to obtain and monitor information about oneself. Both are essential to consciousness, but one can exist without the other.
Say you’re driving a car and the low fuel light comes on. Here, the perception of the fuel-tank light is C1—a mental representation that we can play with: we notice it, act upon it (refill the gas tank) and recall and speak about it at a later date (“I ran out of gas in the boonies!”).
“The first meaning we want to separate (from consciousness) is the notion of global availability,” explains Dehaene in an interview with Science. When you’re conscious of a word, your whole brain is aware of it, in a sense that you can use the information across modalities, he adds.
But C1 is not just a “mental sketchpad.” It represents an entire architecture that allows the brain to draw multiple modalities of information from our senses or from memories of related events, for example.
Unlike subconscious processing, which often relies on specific “modules” competent at a defined set of tasks, C1 is a global workspace that allows the brain to integrate information, decide on an action, and follow through until the end.
Like The Hunger Games, what we call “conscious” is whatever representation, at one point in time, wins the competition to access this mental workspace. The winners are shared among different brain computation circuits and are kept in the spotlight for the duration of decision-making to guide behavior.
Because of these features, C1 consciousness is highly stable and global—all related brain circuits are triggered, the authors explain.
For a complex machine such as an intelligent car, C1 is a first step towards addressing an impending problem, such as a low fuel light. In this example, the light itself is a type of subconscious signal: when it flashes, all of the other processes in the machine remain uninformed, and the car—even if equipped with state-of-the-art visual processing networks—passes by gas stations without hesitation.
With C1 in place, the fuel tank would alert the car computer (allowing the light to enter the car’s “conscious mind”), which in turn checks the built-in GPS to search for the next gas station.
“We think in a machine this would translate into a system that takes information out of whatever processing module it’s encapsulated in, and make it available to any of the other processing modules so they can use the information,” says Dehaene. “It’s a first sense of consciousness.”
Meta-cognition
In a way, C1 reflects the mind’s capacity to access outside information. C2 goes introspective.
The authors define the second facet of consciousness, C2, as “meta-cognition:” reflecting on whether you know or perceive something, or whether you just made an error (“I think I may have filled my tank at the last gas station, but I forgot to keep a receipt to make sure”). This dimension reflects the link between consciousness and sense of self.
C2 is the level of consciousness that allows you to feel more or less confident about a decision when making a choice. In computational terms, it’s an algorithm that spews out the probability that a decision (or computation) is correct, even if it’s often experienced as a “gut feeling.”
C2 also has its claws in memory and curiosity. These self-monitoring algorithms allow us to know what we know or don’t know—so-called “meta-memory,” responsible for that feeling of having something at the tip of your tongue. Monitoring what we know (or don’t know) is particularly important for children, says Dehaene.
“Young children absolutely need to monitor what they know in order to…inquire and become curious and learn more,” he explains.
The two aspects of consciousness synergize to our benefit: C1 pulls relevant information into our mental workspace (while discarding other “probable” ideas or solutions), while C2 helps with long-term reflection on whether the conscious thought led to a helpful response.
Going back to the low fuel light example, C1 allows the car to solve the problem in the moment—these algorithms globalize the information, so that the car becomes aware of the problem.
But to solve the problem, the car would need a “catalog of its cognitive abilities”—a self-awareness of what resources it has readily available, for example, a GPS map of gas stations.
“A car with this sort of self-knowledge is what we call having C2,” says Dehaene. Because the signal is globally available and because it’s being monitored in a way that the machine is looking at itself, the car would care about the low gas light and behave like humans do—lower fuel consumption and find a gas station.
“Most present-day machine learning systems are devoid of any self-monitoring,” the authors note.
But their theory seems to be on the right track. The few examples whereby a self-monitoring system was implemented—either within the structure of the algorithm or as a separate network—the AI has generated “internal models that are meta-cognitive in nature, making it possible for an agent to develop a (limited, implicit, practical) understanding of itself.”
Towards conscious machines
Would a machine endowed with C1 and C2 behave as if it were conscious? Very likely: a smartcar would “know” that it’s seeing something, express confidence in it, report it to others, and find the best solutions for problems. If its self-monitoring mechanisms break down, it may also suffer “hallucinations” or even experience visual illusions similar to humans.
Thanks to C1 it would be able to use the information it has and use it flexibly, and because of C2 it would know the limit of what it knows, says Dehaene. “I think (the machine) would be conscious,” and not just merely appearing so to humans.
If you’re left with a feeling that consciousness is far more than global information sharing and self-monitoring, you’re not alone.
“Such a purely functional definition of consciousness may leave some readers unsatisfied,” the authors acknowledge.
“But we’re trying to take a radical stance, maybe simplifying the problem. Consciousness is a functional property, and when we keep adding functions to machines, at some point these properties will characterize what we mean by consciousness,” Dehaene concludes.
Image Credit: agsandrew / Shutterstock.com Continue reading
Posted in Human Robots
#431371 Amazon Is Quietly Building the Robots of ...
Science fiction is the siren song of hard science. How many innocent young students have been lured into complex, abstract science, technology, engineering, or mathematics because of a reckless and irresponsible exposure to Arthur C. Clarke at a tender age? Yet Arthur C. Clarke has a very famous quote: “Any sufficiently advanced technology is indistinguishable from magic.”
It’s the prospect of making that… ahem… magic leap that entices so many people into STEM in the first place. A magic leap that would change the world. How about, for example, having humanoid robots? They could match us in dexterity and speed, perceive the world around them as we do, and be programmed to do, well, more or less anything we can do.
Such a technology would change the world forever.
But how will it arrive? While true sci-fi robots won’t get here right away—the pieces are coming together, and the company best developing them at the moment is Amazon. Where others have struggled to succeed, Amazon has been quietly progressing. Notably, Amazon has more than just a dream, it has the most practical of reasons driving it into robotics.
This practicality matters. Technological development rarely proceeds by magic; it’s a process filled with twists, turns, dead-ends, and financial constraints. New technologies often have to answer questions like “What is this good for, are you being realistic?” A good strategy, then, can be to build something more limited than your initial ambition, but useful for a niche market. That way, you can produce a prototype, have a reasonable business plan, and turn a profit within a decade. You might call these “stepping stone” applications that allow for new technologies to be developed in an economically viable way.
You need something you can sell to someone, soon: that’s how you get investment in your idea. It’s this model that iRobot, developers of the Roomba, used: migrating from military prototypes to robotic vacuum cleaners to become the “boring, successful robot company.” Compare this to Willow Garage, a genius factory if ever there was one: they clearly had ambitions towards a general-purpose, multi-functional robot. They built an impressive device—PR2—and programmed the operating system, ROS, that is still the industry and academic standard to this day.
But since they were unable to sell their robot for much less than $250,000, it was never likely to be a profitable business. This is why Willow Garage is no more, and many workers at the company went into telepresence robotics. Telepresence is essentially videoconferencing with a fancy robot attached to move the camera around. It uses some of the same software (for example, navigation and mapping) without requiring you to solve difficult problems of full autonomy for the robot, or manipulating its environment. It’s certainly one of the stepping-stone areas that various companies are investigating.
Another approach is to go to the people with very high research budgets: the military.
This was the Boston Dynamics approach, and their incredible achievements in bipedal locomotion saw them getting snapped up by Google. There was a great deal of excitement and speculation about Google’s “nightmare factory” whenever a new slick video of a futuristic militarized robot surfaced. But Google broadly backed away from Replicant, their robotics program, and Boston Dynamics was sold. This was partly due to PR concerns over the Terminator-esque designs, but partly because they didn’t see the robotics division turning a profit. They hadn’t found their stepping stones.
This is where Amazon comes in. Why Amazon? First off, they just announced that their profits are up by 30 percent, and yet the company is well-known for their constantly-moving Day One philosophy where a great deal of the profits are reinvested back into the business. But lots of companies have ambition.
One thing Amazon has that few other corporations have, as well as big financial resources, is viable stepping stones for developing the technologies needed for this sort of robotics to become a reality. They already employ 100,000 robots: these are of the “pragmatic, boring, useful” kind that we’ve profiled, which move around the shelves in warehouses. These robots are allowing Amazon to develop localization and mapping software for robots that can autonomously navigate in the simple warehouse environment.
But their ambitions don’t end there. The Amazon Robotics Challenge is a multi-million dollar competition, open to university teams, to produce a robot that can pick and package items in warehouses. The problem of grasping and manipulating a range of objects is not a solved one in robotics, so this work is still done by humans—yet it’s absolutely fundamental for any sci-fi dream robot.
Google, for example, attempted to solve this problem by hooking up 14 robot hands to machine learning algorithms and having them grasp thousands of objects. Although results were promising, the 10 to 20 percent failure rate for grasps is too high for warehouse use. This is a perfect stepping stone for Amazon; should they crack the problem, they will likely save millions in logistics.
Another area where humanoid robotics—especially bipedal locomotion, or walking, has been seriously suggested—is in the last mile delivery problem. Amazon has shown willingness to be creative in this department with their notorious drone delivery service. In other words, it’s all very well to have your self-driving car or van deliver packages to people’s doors, but who puts the package on the doorstep? It’s difficult for wheeled robots to navigate the full range of built environments that exist. That’s why bipedal robots like CASSIE, developed by Oregon State, may one day be used to deliver parcels.
Again: no one more than Amazon stands to profit from cracking this technology. The line from robotics research to profit is very clear.
So, perhaps one day Amazon will have robots that can move around and manipulate their environments. But they’re also working on intelligence that will guide those robots and make them truly useful for a variety of tasks. Amazon has an AI, or at least the framework for an AI: it’s called Alexa, and it’s in tens of millions of homes. The Alexa Prize, another multi-million-dollar competition, is attempting to make Alexa more social.
To develop a conversational AI, at least using the current methods of machine learning, you need data on tens of millions of conversations. You need to understand how people will try to interact with the AI. Amazon has access to this in Alexa, and they’re using it. As owners of the leading voice-activated personal assistant, they have an ecosystem of developers creating apps for Alexa. It will be integrated with the smart home and the Internet of Things. It is a very marketable product, a stepping stone for robot intelligence.
What’s more, the company can benefit from its huge sales infrastructure. For Amazon, having an AI in your home is ideal, because it can persuade you to buy more products through its website. Unlike companies like Google, Amazon has an easy way to make a direct profit from IoT devices, which could fuel funding.
For a humanoid robot to be truly useful, though, it will need vision and intelligence. It will have to understand and interpret its environment, and react accordingly. The way humans learn about our environment is by getting out and seeing it. This is something that, for example, an Alexa coupled to smart glasses would be very capable of doing. There are rumors that Alexa’s AI will soon be used in security cameras, which is an ideal stepping stone task to train an AI to process images from its environment, truly perceiving the world and any threats it might contain.
It’s a slight exaggeration to say that Amazon is in the process of building a secret robot army. The gulf between our sci-fi vision of robots that can intelligently serve us, rather than mindlessly assemble cars, is still vast. But in quietly assembling many of the technologies needed for intelligent, multi-purpose robotics—and with the unique stepping stones they have along the way—Amazon might just be poised to leap that gulf. As if by magic.
Image Credit: Denis Starostin / Shutterstock.com Continue reading
Posted in Human Robots